What is the 13F Pro Quality Score for MGRX?

13F Pro ranks MANGOCEUTICALS, INC. (MGRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MGRX's current score at https://13fpro.ai/company/MGRX (free sign-up required for the full ranking).

Which hedge funds own the most MGRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MGRX include CITADEL ADVISORS, XTX Topco Ltd, GEODE CAPITAL MANAGEMENT,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MGRX as soon as new 13F filings post.

Where does 13F Pro source MGRX data?

All MANGOCEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. MANGOCEUTICALS, INC. files with the SEC under CIK 1938046. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MGRX in?

MANGOCEUTICALS, INC. (MGRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MGRX research updated on 13F Pro?

MGRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MANGOCEUTICALS, INC.(MGRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1938046 MGRX stock profile & AI dashboard →

13F Pro Quality Score

9.6/100

Rank #2,915 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MGRX Scores 10/100

exact factor attribution · 2026-09-11

MGRX's composite is held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+0.3 pts

53th pct

Institutional flow

-0.8 pts

34th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.3 pts

4th pct

Capital efficiency

-4.5 pts

5th pct

Free cash flow

-6.9 pts

4th pct

Profitability

-7.1 pts

3th pct

Scale

-7.3 pts

1th pct

Revenue growth

-9.6 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MGRX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for MANGOCEUTICALS, INC. (MGRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MGRX at 9.6/100 on a 32-signal composite quality model, placing it at rank #2,915 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), MANGOCEUTICALS, INC. reports quarterly revenue of $68.8K, net income of $-1.3M. Top institutional holders of MGRX by reported 13-F value include CITADEL ADVISORS, XTX Topco Ltd, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. MGRX trades on the Nasdaq exchange and files with the SEC under CIK 1938046. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MGRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MANGOCEUTICALS, INC. directly from SEC EDGAR. MANGOCEUTICALS, INC.'s 13F Pro composite quality score has ranged between 6 and 11 since 2026, currently 9.6 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about MANGOCEUTICALS, INC.

Quirks, history, and lore behind MGRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · micro-cap · listed on Nasdaq · headquartered in Texas.
2
The Numbers
A very small company with revenues in the low millions — this is an early-stage business where growth ambition far outpaces current scale.
3
The History
Founded in the early 2020s, it launched during a boom in direct-to-consumer telehealth and men's wellness services.
4
The Secret
Its core business is prescribing and delivering medications for erectile dysfunction directly to men's doorsteps — no awkward pharmacy lines required.
5
The Lore
The company's name mashes up a tropical fruit with the word for drug-making — a branding choice that is either genius or very confusing, depending on your fruit knowledge.
6
The Giveaway
Ticker MGRX, named after a mango — this tiny Texas telehealth firm wants to be your go-to source for men's sexual health medications, delivered discreetly.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$68.8K

Net Income

Q2 2026

$-1.3M

ROIC

Q2 2026

-33.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-26.0% YoY

$456.0KFY 2025

FY22 $8.9KFY23 $731.5KFY24 $615.9KFY25 $456.0K

Net Income

-137.1% YoY

$-20.6MFY 2025

FY22 $-2.0MFY23 $-9.2MFY24 $-8.7MFY25 $-20.6M

Operating Income

-126.2% YoY

$-18.0MFY 2025

FY22 $-2.0MFY23 $-9.2MFY24 $-8.0MFY25 $-18.0M

EPS (Diluted)

+54.8% YoY

$-2.17FY 2025

FY22 $-0.01FY23 $-0.57FY24 $-4.80FY25 $-2.17

Total Assets

+4.7% YoY

$16.1MFY 2025

FY22 $1.0MFY23 $1.1MFY24 $15.4MFY25 $16.1M

Op. Cash Flow

-20.3% YoY

$-5.9MFY 2025

FY22 $-1.3MFY23 $-7.0MFY24 $-4.9MFY25 $-5.9M

Free Cash Flow

—FY 2025

FY22 $-1.4MFY23 $-7.0MFY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$456.0K -26.0%	$615.9K -15.8%	$731.5K +8083.2%	$8.9K	—
Net Income	$-20.6M -137.1%	$-8.7M +5.5%	$-9.2M -361.1%	$-2.0M	—
Operating Income	$-18.0M -126.2%	$-8.0M +13.5%	$-9.2M -362.9%	$-2.0M	—
EPS (Diluted)	$-2.17 +54.8%	$-4.80 -739.2%	$-0.57 -4403.9%	$-0.01	—
Total Assets	$16.1M +4.7%	$15.4M +1362.8%	$1.1M +4.7%	$1.0M	—
Operating Cash Flow	$-5.9M -20.3%	$-4.9M +30.5%	$-7.0M -419.7%	$-1.3M	—
Free Cash Flow	—	—	$-7.0M -403.8%	$-1.4M	—

Get alerted when MGRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MANGOCEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MGRX

CITADEL ADVISORS LLC
$128.8K338,964 sh
XTX Topco Ltd
$70.8K186,256 sh
GEODE CAPITAL MANAGEMENT, LLC
$59.4K156,243 sh
Ikarian Capital, LLC
$52.5K138,146 sh
VANGUARD CAPITAL MANAGEMENT LLC
$46.8K123,041 sh
VANGUARD FIDUCIARY TRUST CO
$21.7K57,163 sh
BOOTHBAY FUND MANAGEMENT, LLC
$14.6K38,441 sh
NORTHERN TRUST CORP
$14.3K37,579 sh
Ackerman Capital Advisors, LLC
$13.1K34,500 sh
HRT FINANCIAL LP
$13.0K36,003 sh

Fund	Value	Shares
CITADEL ADVISORS LLC	$128.8K	338,964
XTX Topco Ltd	$70.8K	186,256
GEODE CAPITAL MANAGEMENT, LLC	$59.4K	156,243
Ikarian Capital, LLC	$52.5K	138,146
VANGUARD CAPITAL MANAGEMENT LLC	$46.8K	123,041
VANGUARD FIDUCIARY TRUST CO	$21.7K	57,163
BOOTHBAY FUND MANAGEMENT, LLC	$14.6K	38,441
NORTHERN TRUST CORP	$14.3K	37,579
Ackerman Capital Advisors, LLC	$13.1K	34,500
HRT FINANCIAL LP	$13.0K	36,003

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MGRX on your watchlist

Track score changes the day MANGOCEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MGRX a good stock to buy?

13F Pro's AI-powered analysis of MANGOCEUTICALS, INC. (MGRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MGRX are available on the MGRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MGRX is classified as a small company.

Which hedge funds own MGRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MGRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MANGOCEUTICALS, INC.'s investment landscape.